Literature DB >> 29885688

Pulmonary hypertension registry of Kerala, India (PRO-KERALA) - Clinical characteristics and practice patterns.

S Harikrishnan1, G Sanjay2, M Ashishkumar3, Jaideep Menon4, Gopalan Nair Rajesh5, Raman Krishna Kumar4, A George Koshy6, Thankachan V Attacheril7, Raju George8, Eapen Punnoose9, S M Ashraf10, S R Arun11, Mohammed Cholakkal12, Panniyammakal Jeemon2.   

Abstract

BACKGROUND: Epidemiological data on pulmonary hypertension (PH) are scarce from developing countries including India.
METHODS: We established a multi-center registry of PH, the PRO-KERALA registry, in Kerala, India. Fifty hospitals enrolled consecutive adult (>18 years) patients for one year. Echocardiographic criteria (right ventricular systolic pressure - RVSP > 50 mmHg) or invasively obtained mean pulmonary artery pressure > 25 mmHg was the criteria for entry.
RESULTS: There were 2003 patients (52% Women, mean age 56 ± 16.1 years) enrolled. The mean RVSP was 68.2 (SD = 17.9) mmHg. Majority of the study participants (59%) belonged to group 2 of the WHO Nice Classification 2013 (PH secondary to left heart disease). One-fifth (21.2%) belonged to group 1, while 13.3%, 3.8% and 2.4% of the study population belonged to groups 3, 4 and 5 respectively. More than a quarter (27%) reported PH due to left heart disease with valvular disease etiology; while 20.7% had coronary artery disease. The other common etiological factors were chronic obstructive pulmonary disease (10.6%), congenital heart disease (14.6%), idiopathic pulmonary hypertension (5.8%), and chronic thromboembolic pulmonary hypertension (3.8%). Only one of two patients with pulmonary artery hypertension was receiving PH specific therapies. The use of combination therapy was negligible and PH-specific therapies were prescribed off-label to a small proportion of patients too.
CONCLUSION: PRO-KERALA is the first PH registry from South Asia and the second largest globally. Left heart diseases attribute to three fifths of patients with PH. Utilization rates of PH specific drug therapies are remarkably lower than the Western population.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29885688     DOI: 10.1016/j.ijcard.2018.02.036

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  1 in total

1.  Current status and barriers in pulmonary hypertension care delivery in India: A qualitative analysis.

Authors:  Anand Reddy Maligireddy; Supriya Shore; A Sreenivas Kumar; S Harikrishnan; S Ajit Mullasari; B K Sastry; Sameer Gupta; Nikhil Choudhary; Auras R Atreya; Sonali Arora; Victor M Moles; Vallerie V Mclaughlin; Vikas Aggarwal
Journal:  Pulm Circ       Date:  2022-04-01       Impact factor: 2.886

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.